[Authorization for off-label use may not be beneficial for the Brazilian Unified National Health System].
作者信息
Caetano Rosângela, Lopes Luciane Cruz, Santos Gustavo Mendes Lima, Osorio-de-Castro Claudia Garcia Serpa
机构信息
Instituto de Medicina Social Hesio Cordeiro, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.
Programa de Pós-graduação em Ciências Farmacêuticas, Universidade de Sorocaba, Sorocaba, Brasil.
出版信息
Cad Saude Publica. 2023 Jun 26;39(6):e00085423. doi: 10.1590/0102-311XPT085423. eCollection 2023.
Abstract
摘要
相似文献
1
[Authorization for off-label use may not be beneficial for the Brazilian Unified National Health System].[超说明书用药的授权可能对巴西统一国家卫生系统并无益处]
Cad Saude Publica. 2023 Jun 26;39(6):e00085423. doi: 10.1590/0102-311XPT085423. eCollection 2023.
2
[Could authorization for off-label use be beneficial to the Brazilian Unified National Health System?].[药品未注册用法的授权对巴西统一国家卫生系统有益吗？]
Cad Saude Publica. 2023 Jun 26;39(6):e00032623. doi: 10.1590/0102-311XPT032623. eCollection 2023.
3
The resilience of Brazilian Unified National Health System in the context of the COVID-19 pandemic: how to strengthen?新冠疫情背景下巴西统一国家卫生系统的韧性：如何加强？
Cad Saude Publica. 2022 Oct 14;38(10):e00097522. doi: 10.1590/0102-311XPT097522. eCollection 2022.
4
A Multi-Criteria Approach to Assess the Performance of the Brazilian Unified Health System.一种评估巴西统一卫生系统绩效的多标准方法。
Int J Environ Res Public Health. 2022 Sep 13;19(18):11478. doi: 10.3390/ijerph191811478.
5
The Brazilian Unified National Health System and the civilizational project: scenarios, alternatives, and proposals.巴西统一国家卫生系统与文明项目：情景、选择与建议。
Cad Saude Publica. 2021 Jun 4;37(6):e00116621. doi: 10.1590/0102-311X00116621.
6
Between intentions and contingencies, old programs and demands for new nutritional care practices in the Brazilian Unified National Health System.在巴西统一国家卫生系统中，旧有方案与新营养护理实践需求之间的意图与意外情况。
Cad Saude Publica. 2021 Oct 29;37Suppl 1(Suppl 1):e00050221. doi: 10.1590/0102-311X00050221. eCollection 2021.
7
The Constitutional Amendment Proposition 241/2016 and the Brazilian Unified National Health System: impacts on research and on industry.《2016年宪法修正案第241号提案》与巴西统一国家卫生系统：对研究和产业的影响
Cad Saude Publica. 2016 Dec 15;32(12):e00182816. doi: 10.1590/0102-311X00182816.
8
Incorporation and use of medicines in the Brazilian Unified National Health System: changes and risks of new Ministry of Health legislation.巴西统一国家卫生系统中药物的纳入与使用：巴西卫生部新立法的变化与风险
Cad Saude Publica. 2023 Feb 17;39(2):e00148222. doi: 10.1590/0102-311XPT148222. eCollection 2023.
9
[Lack of management and institutional support for Integrative and Complementary Practices in the Brazilian Unified National Health System].[巴西统一国家卫生系统中综合与补充疗法缺乏管理和机构支持]
Cad Saude Publica. 2020;36(6):e00062320. doi: 10.1590/0102-311x00062320. Epub 2020 Jul 6.
10
Promotion of body practices and physical activities in the Brazilian Unified National Health System: changes in sight, but to which direction?巴西统一国家卫生系统中身体锻炼和体育活动的推广：前景有所变化，但朝着哪个方向发展？
Cad Saude Publica. 2022 Sep 5;38(8):e00095722. doi: 10.1590/0102-311XPT095722. eCollection 2022.
本文引用的文献
1
[Could authorization for off-label use be beneficial to the Brazilian Unified National Health System?].[药品未注册用法的授权对巴西统一国家卫生系统有益吗？]
Cad Saude Publica. 2023 Jun 26;39(6):e00032623. doi: 10.1590/0102-311XPT032623. eCollection 2023.
2
Incorporation and use of medicines in the Brazilian Unified National Health System: changes and risks of new Ministry of Health legislation.巴西统一国家卫生系统中药物的纳入与使用：巴西卫生部新立法的变化与风险
Cad Saude Publica. 2023 Feb 17;39(2):e00148222. doi: 10.1590/0102-311XPT148222. eCollection 2023.
3
Off-Label, but on-Evidence? A Review of the Level of Evidence for Pediatric Pharmacotherapy.超适应证用药，但有证据支持？儿科药物治疗的证据水平评价综述。
Clin Pharmacol Ther. 2022 Dec;112(6):1243-1253. doi: 10.1002/cpt.2736. Epub 2022 Sep 25.
4
Incorporation of medicines in the Unified Health System (SUS): comparison between oncology and the specialized component of pharmaceutical care.将药品纳入统一卫生系统（SUS）：肿瘤学与药物治疗专业部分的比较。
Cien Saude Colet. 2022 Jun;27(6):2471-2479. doi: 10.1590/1413-81232022276.16282021. Epub 2021 Nov 5.
5
How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.与其他治疗1-3型脊髓性肌萎缩症的方法相比，利司扑兰的效果如何：一项系统文献综述和间接治疗比较
J Comp Eff Res. 2022 Apr;11(5):347-370. doi: 10.2217/cer-2021-0216. Epub 2022 Jan 18.
6
Patient and public involvement in health technology decision-making processes in Brazil.巴西卫生技术决策过程中的患者和公众参与。
Rev Saude Publica. 2020 Dec 11;54:136. doi: 10.11606/s1518-8787.2020054002453. eCollection 2020.
7
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients.标签内用药还是标签外用药？克服监管和财务障碍，将重新利用的药物带给癌症患者。
Front Pharmacol. 2020 Jan 31;10:1664. doi: 10.3389/fphar.2019.01664. eCollection 2019.
8
[The incorporation of nusinersen by the Brazilian Unified National Health System: critical thoughts on the institutionalization of health technology assessment in Brazil].[巴西统一国家卫生系统纳入诺西那生：对巴西卫生技术评估制度化的批判性思考]
Cad Saude Publica. 2019 Aug 29;35(8):e00099619. doi: 10.1590/0102-311X00099619.
9
Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.基层医疗中抗抑郁药的非适应证用药：基于适应证的电子处方系统处方描述性研究
BMJ. 2017 Feb 21;356:j603. doi: 10.1136/bmj.j603.
10
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.成人人群中药物的标签外使用与药物不良事件的关联性。
JAMA Intern Med. 2016 Jan;176(1):55-63. doi: 10.1001/jamainternmed.2015.6058.
Zotero 插件